Lenacapavir will be available at low cost in 120 poor countries. But nearly all of Latin America was excluded from a deal ...
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
In Argentina, patients and medical professionals are alarmed by President Javier Milei's proposed spending cuts that are affecting HIV/AIDS treatment and prevention. The austerity measures, aimed at ...
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
It’s been called the closest the world has ever come to a vaccine against AIDS. The twice-yearly shot was 100% effective in ...
Current health news highlights include Sanofi's $1 billion investment in a Beijing insulin site, New Zealand's poultry export ...